Breath Therapeutics Announces Appointment of Melissa Yeager as Chief Regulatory Officer

Breath Therapeutics BV announced today the appointment of Melissa Yeager as Chief Regulatory Officer. Ms Yeager will join the executive management and lead Breath Therapeutics’ regulatory activities.

BREATH THERAPEUTICS ANNOUNCES APPOINTMENT OF MELISSA YEAGER AS CHIEF REGULATORY OFFICER 

 

  • Top-tier regulatory affairs executive joins executive management
  • Substantial strengthening for lead program in Bronchiolitis Obliterans 

Munich, Frankfurt, Boston, Juli 3rd, 2017 — Breath Therapeutics BV (Breath Therapeutics), a company developing advanced drug-aerosol therapeutics in pulmonary orphan indications, announced today the appointment of Melissa Yeager as Chief Regulatory Officer. Ms Yeager will join the executive management and lead Breath Therapeutics’ regulatory activities.

This new position adds important expertise in line with Breath Therapeutics 's lead program BOSTON, which is developing a first-in-class inhalation therapy for treatment of Bronchiolitis Obliterans, a lethal orphan respiratory disease. Furthermore, this position leverages the continued extension of Breath Therapeutics´ development pipeline. 

“Melissa is a highly regarded leader who has successfully led global regulatory activities with an impressive track record of FDA and EMA approved drug device products in pulmonary orphan indications," said Jens Stegemann, PhD, Chief Executive Officer of Breath Therapeutics. "She joins Breath Therapeutics as we are making steady progress in planning the phase 3 studies of our lead development program, BOSTON, in Bronchiolitis Obliterans and continue also to prepare a phase 2 study for a line extension indication.

Prior to joining Breath Therapeutics, Ms. Yeager was an independent regulatory consultant and held executive leadership positions as Chief Operating Officer at Cardeas, and Vice President Regulatory Affairs at Gilead. Prior to Gilead, Ms. Yeager was Director Regulatory Affairs at Corus and Pathogenesis. During that time she was responsible for the successful NDA and EMA approval of two inhaled drug device products for Cystic Fibrosis, Tobi® and Cayston®. Ms. Yeager is a member of the University of Washington Robinson CenterAdvisory Board of Trustees and the Bruke Museum. She earned her BA in Human Biology from the Stanford University of California and JD at Santa Clara University, California, USA.

 

About Breath Therapeutics

Breath Therapeutics is a startup pharmaceutical company specializing in advanced and first-in-class inhalation therapies for severe respiratory diseases. For its clinical development, the company is using proprietary drug formulations optimized for inhaled administration with exclusively licenced, high performance nebulizers. Breath Therapeutics is focussing on integrated therapy solutions in the interaction between diagnostic, therapy and eHealth therapy control. The clinical development program BOSTON is addressing the treatment of Bronchiolitis Obliterans Syndrome (BOS) in patients after lung transplantation. PARI Pharma, a leading nebulizer company, is strategic partner and technology licensee for the BOS development program. Breath Therapeutics is Germany and US based with offices in Frankfurt, Munich and Boston. 

  

For more information, please visit www.breath-therapeutics.com of contact the company by email contact@no-spam-pleasebreath-therapeutics.com.